In this respect, although several SIRT1/AMPK activators have been proposed for NAFLD treatment [41,42], we think that silibinin can be more effective than the others because it can beneficially modulate almost all the molecular mechanisms associated with onset and progression of NAFLD [43]. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.